micronavigation ELN path item Leukemias path item MDS path item Publications  · 
Workpackage 8

Publications



  1. Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, Denzlinger C, Muus P, Stauder R, Berneman Z, Pruijt J, Nobile F, Cassibba V, Marie JP, Beeldens F, Baila L, Vignetti M, de Witte T.: Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
    Leukemia Oct;19(10):1768-73, 2005
    Subjects: MDS
  2. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrere F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T; EORTC/GIMEMA Leukemia Group: Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.
    Blood 2005 Jul 1;106(1):27-34. Epub 2005 Mar 10
    Subjects: MDS
  3. Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ: Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
    Br J Haematol. 2011 Jun;153(5):568-81. [pmid:21488861]
    Subjects:
  4. Barouk-Simonet E, Soenen-Cornu V, Roumier C, Cosson A, Lai JL, Fenaux P, Preudhomme C.: Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases.
    Cancer Genet Cytogenet 2005 Mar;157(2):118-26
    Subjects: MDS
  5. Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, Fan AC, Felsher DW, Whetton A, Pla M, West R, Fenaux P, Chomienne C, Padua RA: BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
    Blood 2013 Oct 17;122(16):2864-76. [pmid:23943652]
    Subjects: AML · MDS
  6. Bowen DT.: Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Semin Oncol. 2005 Aug;32(4 Suppl 5):S16-23
    Subjects: MDS
  7. Braulke F, Schanz J, Jung K, Shirneshan K, Schulte K, Schuetze C, Steffens R, Trümper L, Haase D: FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients.
    Leuk Res. 2010 Oct;34(10):1296-301. [pmid:20226527]
    Subjects:
  8. Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, Bordessoule D, Stamatoullas A, Castaigne S, Terré C, Eclache V, Fenaux P, Adès L: Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
    Leuk Res. 2011 Jul;35(7):863-7. [pmid:21396711]
    Subjects:
  9. Carlsten M, Baumann BC, Simonsson M, Jädersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG, Hellström-Lindberg E, Malmberg KJ: Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
    Leukemia. 2010 Sep;24(9):1607-16. [pmid:20613786]
    Subjects:
  10. Cazzola M, Malcovati L: Prognostic classification and risk assessment in myelodysplastic syndromes.
    Hematol Oncol Clin North Am. 2010 Apr;24(2):459-68. [pmid:20359637]
    Subjects:
  11. Cazzola M, Della Porta MG, Travaglino E, Malcovati L.: Classification and prognostic evaluation of myelodysplastic syndromes.
    Semin Oncol. 2011 Oct;38(5):627-34. [pmid:21943669]
    Subjects:
  12. Chen C, Bowen DT, Giagounidis AA, Schlegelberger B, Haase S, Wright EG: Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).
    Leukemia. 2010 Nov;24(11):1875-84. [pmid:20739954]
    Subjects:
  13. Cuijpers ML, Raymakers RA, Mackenzie MA, de Witte TJ, Swinkels DW: Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.
    Br J Haematol. 2010 May;149(3):322-33. [pmid:20067561]
    Subjects:
  14. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M: Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
    Haematologica. 2011 Mar;96(3):441-9. [pmid:21134982]
    Subjects:
  15. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group: A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
    Blood. 2011 Oct 6;118(14):3765-76. [pmid:21753188]
    Subjects:
  16. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen A, Mueller T, Haas R, Gattermann N, Aul C.: Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
    Leukemia 2005 Dec;19(12):2223-31
    Subjects: MDS
  17. Germing U,Strupp C,Kuendgen A,Isa S,Knipp S,Hildebrandt B,Giagounidis A,Aul C,Gattermann N,Haas R: Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
    Haematologica 2006 Dec;91(12):1596-604 [pmid:17145595]
    Subjects: MDS
  18. Germing U,Strupp C,Kuendgen A,Aivado M,Giagounidis A,Hildebrandt B,Aul C,Haas R,Gattermann N: Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.
    British journal of haematology 2006 Jan;132(2):162-7 [pmid:16398650]
    Subjects: MDS
  19. Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lubbert M, Ganser A, Aivado M, Heinsch M, Aul C.: Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
    Ann Hematol 2005 Jun;84(6):389-94
    Subjects: MDS
  20. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators: Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Leuk Res. 2010 Sep;34(9):1143-50. [pmid:20451251]
    Subjects:
  21. Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B: Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Ann Hematol. 2010 Apr;89(4):365-74. [pmid:19855965]
    Subjects:
  22. Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK: Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
    Ann Hematol. 2010 Sep;89(9):841-50. [pmid:20567826]
    Subjects:
  23. Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E: Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
    Br J Haematol. 2010 Aug;150(3):293-302. [pmid:20497178]
    Subjects:
  24. Gueller S, Komor M, Nowak D, Baldus CD, de Vos S, Hoelzer D, Ottmann OG, Hofmann WK: Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome.
    Exp Hematol. 2010 Sep;38(9):718-32, 732.e1-6. [pmid:20621626]
    Subjects:
  25. Hellstrom-Lindberg E.: Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents
    Hematology (Am Soc Hematol Educ Program) 2005;:161-6
    Subjects: MDS
  26. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM): Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Leukemia. 2011 Jul;25(7):1147-52. [pmid:21494260]
    Subjects:
  27. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E.: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
    Blood 2005 Aug 1;106(3):803-11
    Subjects: MDS
  28. Jädersten M, Hellström-Lindberg E: New clues to the molecular pathogenesis of myelodysplastic syndromes.
    Exp Cell Res. 2010 May 1;316(8):1390-6. [pmid:20211165]
    Subjects:
  29. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellström-Lindberg E, Mufti GJ: TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
    J Clin Oncol. 2011 May 20;29(15):1971-9. [pmid:21519010]
    Subjects:
  30. Kroger N, Brand R, van Biezen A, Bron D, Blaise D, Hellstrom-Lindberg E, Gahrton G, Powles R, Littlewood T, Chapuis B, Zander A, Koza V, Niederwieser D, de Witte T: Myelodysplastic Syndromes Subcommittee of the Chronic Leukaemia Working Party, European Blood and Marrow Transplantation Group. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes
    Bone Marrow Transplant 2005 Jan;35(1):37-43
    Subjects: MDS
  31. Kroger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T.: Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome
    Bone Marrow Transplant 2005 Nov 21
    Subjects: MDS
  32. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP: Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
    J Clin Oncol. 2010 Jan 20;28(3):437-44. [pmid:20008626]
    Subjects:
  33. Kröger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T; MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT): Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.
    Haematologica. 2011 Feb;96(2):291-7. [pmid:20971823]
    Subjects:
  34. Kühne F, Mittendorf T, Germing U, Tesch H, Weinberg R, Grabenhorst U, Mohr A, Lipp R, von der Schulenburg JM: Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective.
    Ann Hematol. 2010 Dec;89(12):1239-47. [pmid:20574731]
    Subjects:
  35. Lindberg EH.: Strategies for biology- and molecular-based treatment of myelodysplastic syndromes
    Curr Drug Targets 2005 Sep;6(6):713-25
    Subjects: MDS
  36. Loh ML, Martinelli S, Cordeddu V, Reynolds MG, Vattikuti S, Lee CM, Wulfert M, Germing U, Haas P, Niemeyer C, Beran ME, Strom S, Lubbert M, Sorcini M, Estey EH, Gattermann N, Tartaglia M.: Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Leuk Res 2005 Apr;29(4):459-62 [pmid:0015725481]
    Subjects: MDS
  37. Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, Schlegelberger B, Göhring G: Telomere shortening and chromosomal instability in myelodysplastic syndromes.
    Genes Chromosomes Cancer. 2010 Mar;49(3):260-9. [pmid:19998444]
    Subjects:
  38. Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, Leiblein S, Al-Ali HK, Edelmann J, Thiery J, Niederwieser D: Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
    Leukemia. 2011 Mar;25(3):498-505. [pmid:21135860]
    Subjects:
  39. Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L: Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience
    Leuk Res. 2011 Nov;35(11):1444-8. [pmid:21715006]
    Subjects:
  40. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, Beelen D, Devergie A, Alessandrino E, Willemze R, Ruutu T, Boogaerts M, Falda M, Jouet JP, Niederwieser D, Kroger N, Mufti GJ, De Witte TM: Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
    J Clin Oncol. 2010 Jan 20;28(3):405-11. [pmid:20008642]
    Subjects:
  41. Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, Ulmer H, Stauder R: Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Crit Rev Oncol Hematol. 2011 May;78(2):150-61. [pmid:20580567]
    Subjects:
  42. Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW: Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    J Clin Oncol. 2011 May 20;29(15):1987-96. [pmid:21483003]
    Subjects:
  43. Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E, Maffioli M, Bernasconi P, Lazzarino M, Invernizzi R, Cazzola M.: Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome
    Leukemia 2005 May;19(5):776-83 [pmid:0015789068]
    Subjects: MDS
  44. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
    J Clin Oncol 2005 Oct 20;23(30):7594-603 [pmid:0016186598]
    Subjects: MDS
  45. Mallo M, Luño E, Sanzo C, Cervera J, Haase D, Schanz J, García-Manero G, del Cañizo C, Sanz GF, Solé F: Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome.
    Leuk Res. 2011 Jun;35(6):834-6. [pmid:21269692]
    Subjects:
  46. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MÁ, Valencia A, Florensa L, Sanz GF, Haase D, Solé F: Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
    Leukemia. 2011 Jan;25(1):110-20. [pmid:20882045]
    Subjects:
  47. Mossner M, Hopfer O, Nowak D, Baldus CD, Neumann U, Kmetsch A, Benlasfer O, John T, Perka C, Thiel E, Hofmann WK: Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature.
    Exp Hematol. 2010 Aug;38(8):661-5. [pmid:20399247]
    Subjects:
  48. Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U: Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.
    Leuk Res. 2011 Dec;35(12):1591-6. [pmid:21708407]
    Subjects:
  49. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH: Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
    Nat Genet. 2010 Aug;42(8):665-7. [pmid:20601954]
    Subjects:
  50. Nilsson-Ehle H, Birgegård G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engström LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellström-Lindberg E: Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
    Eur J Haematol. 2011 Sep;87(3):244-52. [pmid:21623919]
    Subjects:
  51. Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M, Stauder R, Giagounidis A, Valent P, Pfeilstöcker M: Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.
    Ann Oncol. 2010 Jan;21(1):120-5. [pmid:19605511]
    Subjects:
  52. Nolte F, Hofmann WK: Molecular mechanisms involved in the progression of myelodysplastic syndrome.
    Future Oncol. 2010 Mar;6(3):445-55. [pmid:20222800]
    Subjects:
  53. Pitako JA, Haas PS, Van den Bosch J, Muller-Berndorff H, Kundgen A, Germing U, Wijermans PW, Lubbert M.: Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine
    Ann Hematol 2005 Dec;84 Suppl 13:25-31
    Subjects: MDS
  54. Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F: Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.
    Leuk Res. 2010 Nov;34(11):1430-6. [pmid:20580086]
    Subjects:
  55. Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Amé S, Tertian G, Slama B, Fenaux P, Dreyfus F: Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.
    Leuk Res. 2011 Nov;35(11):1530-3. [pmid:21803419]
    Subjects:
  56. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Verma A, Norbury CJ, Hellström-Lindberg E, Wainscoat JS, Boultwood J: Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
    Leukemia. 2010 Apr;24(4):756-64. [pmid:20220779]
    Subjects:
  57. Platzbecker U, Aul C, Ehninger G, Giagounidis A: Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil.
    Ann Hematol. 2010 Apr;89(4):427-8. [pmid:19714330]
    Subjects:
  58. Porwit A: Role of flow cytometry in diagnostics of myelodysplastic syndromes--beyond the WHO 2008 classification.
    Semin Diagn Pathol. 2011 Nov;28(4):273-82. [pmid:22195405]
    Subjects: MDS
  59. Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Adès L, Quesnel B, Beach CL, Fenaux P, Vey N: Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.
    J Clin Oncol. 2011 Aug 20;29(24):3322-7. [pmid:21788559]
    Subjects:
  60. Reins J, Mossner M, Neumann M, Platzbecker U, Schumann C, Thiel E, Hofmann WK: Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS.
    Leuk Res. 2010 Dec;34(12):1610-6. [pmid:20471677]
    Subjects:
  61. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P; GFM (Groupe Francophone des Myélodysplasies): Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res. 2010 Jul;34(7):864-70. [pmid:20129667]
    Subjects:
  62. Sanz MA, Fenaux P, Lo Coco F: European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence
    Haematologica 2005 Sep;90(9):1231-5 [pmid:16154847]
    Subjects: MDS
  63. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I.: Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms
    Leukemia 2005 Jan;19(1):103-11
    Subjects: MDS
  64. Strupp C,Gattermann N,Giagounidis A,Aul C,Hildebrandt B,Haas R,Germing U: Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
    Leukemia research 2003 May;27(5):397-404 [pmid:12620291]
    Subjects: MDS
  65. Schroeder T, Ruf L, Bernhardt A, Hildebrandt B, Aivado M, Aul C, Gattermann N, Haas R, Germing U: Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.
    Ann Oncol. 2010 Nov;21(11):2267-71. [pmid:20439346]
    Subjects:
  66. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM): Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
    Blood. 2010 Nov 11;116(19):3735-42. [pmid:20664061]
    Subjects:
  67. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A: Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    J Clin Oncol. 2011 Jun 20;29(18):2499-506. [pmid:21576631]
    Subjects:
  68. Tobiasson M, Olsson R, Hellström-Lindberg E, Mattsson J: Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT.
    Bone Marrow Transplant. 2011 May;46(5):719-26. [pmid:20697367]
    Subjects:
  69. de Witte T: Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?
    Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S46-8. [pmid:22035747]
    Subjects:
  70. Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppele GJ, van de Loosdrecht AA: Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.
    Blood. 2010 Mar 4;115(9):1779-84. [pmid:20038788]
    Subjects:
  71. Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S: EORTC Leukemia Cooperative Group. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
    Leukemia 2005 Nov;19(11):1929-33
    Subjects: MDS

 

Print this Document   Sitemap   Contact  
EUTOS
EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe More ...


 
top